Arachidonic acid
|
Basic information |
| Metabolite name | Arachidonic acid |
 | HMDB0001043 |
 |
C00219 |
 |
444899 |
| Synonyms | 5,8,11,14-Eicosatetraenoic acid; |
| No. of studies | 59 |
|
Basic information |
| Metabolite name | Arachidonic acid |
| HMDB0001043 |
|
C00219 |
|
444899 |
| Synonyms | 5,8,11,14-Eicosatetraenoic acid; |
| No. of studies | 59 |
|
Relationship between Arachidonic acid and depression (count: 59) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M002 | Type1 | CUMS group vs. control group | Thalamus | Sprague-Dawley rat | Up |
| Study M018 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M028 | Type2 | sertraline group 4-week treatment vs. baseline | Serum | Human | Down |
| Study M042 | Type3 | fluoxetine group vs. control group | Plasma | Rhesus monkey | Down |
| Study M076 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M076 | Type2 | CUMS + Anemarrhena saponins and Lilium saponins group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M083 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M084 | Type1 | melancholic depressed group vs. control group | Plasma | Human | Down |
| Study M087 | Type2 | ketamine group 2-h vs. baseline | Plasma | Human | Up |
| Study M092 | Type1 | LPS group vs. control group | Prefrontal cortex | CD-1 mouse | Up |
| Study M1007 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M1007 | Type2 | CUMS + bifid triple viable capsules group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M1019 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M1024 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Up |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | CA3 region of hippocampus | ICR mouse | Down |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | Serum | ICR mouse | Down |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | CA1 region of hippocampus | ICR mouse | Down |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | DG region of hippocampus | ICR mouse | Down |
| Study M1032 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M104 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M104 | Type2 | CUMS + BH group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M104 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M104 | Type2 | CUMS + ZB group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M1087 | Type1 | CSDS group vs. control group | Faece | C57BL/6 mouse | Up |
| Study M1093 | Type1 | CSDS group vs. control group | Serum | C57BL/6N mouse | Down |
| Study M1096 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M1096 | Type2 | CUMS + low dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + middle dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + high dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + fluoxetine group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M110 | Type1 | SD group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M1111 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M1111 | Type1 | CUMS group vs. control group | Plasma | C57BL/6 mouse | Down |
| Study M1111 | Type1 | CUMS group vs. control group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M1111 | Type2 | CUMS + rTMS group vs. CUMS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M1111 | Type2 | CUMS + rTMS group vs. CUMS group | Plasma | C57BL/6 mouse | Up |
| Study M130 | Type2 | CSDS + venlafaxine group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M130 | Type2 | CSDS + DG group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M131 | Type1 | LH group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M131 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M131 | Type1 | SD group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M181 | Type3 | venlafaxine group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M207 | Type1 | depressed group vs. control group | Serum | Kunming mouse | Down |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M209 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M460 | Type1 | depressed group vs. control group | Liver | Kunming mouse | Up |
| Study M464 | Type1 | drug-treatment MDD group vs. control group | Plasma | Human | Down |
| Study M464 | Type1 | drug-naive MDD group vs. control group | Plasma | Human | Down |
| Study M472 | Type3 | (2R,6R)-HNK group vs. control group | PC12 cell | Rat | Down |
| Study M548 | Type1 | FSL group vs. FRL group, left hippocampus | Hippocampus | Sprague-Dawley rat | Down |
| Study M548 | Type1 | FSL group vs. FRL group, left prefrontal cortex | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M548 | Type1 | FSL group vs. FRL group, right hippocampus | Hippocampus | Sprague-Dawley rat | Up |
| Study M555 | Type1 | FMT group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M569 | Type2 | LPS + HPF group vs. LPS group | Hippocampus | ICR mouse | Up |
| Study M569 | Type2 | LPS + HPF group vs. LPS group | Serum | ICR mouse | Up |
| Study M573 | Type1 | CSDS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M582 | Type3 | control + fluoxetine group vs. control group | Hippocampus | C57BL/6N mouse | Up |
| Study M592 | Type1 | CUMS group vs. control group, LC-MS | Liver | Sprague-Dawley rat | Up |
| Study M592 | Type2 | CUMS + high dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M592 | Type2 | CUMS + low dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M592 | Type2 | CUMS + venlafaxine group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M593 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M593 | Type2 | CUMS + high dose of Radix Bupleuri-Radix Paeoniae Alba herb pair group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M593 | Type2 | CUMS + low dose of Radix Bupleuri-Radix Paeoniae Alba herb pair group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M593 | Type2 | CUMS + venlafaxine group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M598 | Type1 | MS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M600 | Type2 | high-fat diet + fish oil group vs. high-fat diet group | Forebrain | C57BL/6J mouse | Down |
| Study M616 | Type1 | CUMS group vs. control group | Olfactory bulb | Sprague-Dawley rat | Down |
| Study M632 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M670 | Type2 | corticosterone + nicotinamide mononucleotide group vs. corticosterone group | Liver | C57/BL6 mouse | Down |
| Study M681 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M681 | Type2 | CUMS + Chaihu Shu Gan San group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M690 | Type2 | CUMS + high dose of Zhi-zi-chi decoction group vs. CUMS group | Serum | Balb/c mouse | Up |
| Study M691 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M691 | Type2 | CUMS + low dose of Baishao group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M691 | Type2 | CUMS + low dose of Chaihu group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M691 | Type2 | CUMS + low dose of Chaihu-Baishao group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M696 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M696 | Type2 | CUMS + liquiritin group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M696 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M712 | Type1 | depression group vs. control group | Amygdala | Cynomolgus monkey | Down |
| Study M744 | Type1 | CUS transplant group vs. control transplant group | Hippocampus | Sprague-Dawley rat | Up |
| Study M769 | Type1 | CSDS group vs. control group | Amygdala | Sprague-Dawley rat | Up |
| Study M774 | Type1 | MDD group vs. control group | Serum | Human | Down |
| Study M775 | Type1 | prenatal stress group vs. control group | Brain | Swiss Webster mouse | Down |
| Study M784 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M784 | Type2 | CUMS + fluoxetine group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M784 | Type2 | CUMS + liquiritin group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M789 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M789 | Type2 | CUMS + liquiritin group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M789 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M800 | Type3 | fluoxetine group vs. control group | Prelimbic cortex | Rhesus monkey | Down |
| Study M858 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M887 | Type1 | CUMS group vs. control group | Serum | C57BL/6J mouse | Down |
| Study M888 | Type1 | CUMS microbiota group vs. control microbiota group | Serum | C57BL/6J mouse | Down |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M935 | Type3 | tianeptine group vs. control group | Hippocampus | Wistar rat | Up |
| Study M935 | Type4 | chronic social isolation + tianeptine group vs. chronic social isolation + tianeptine resilient group | Hippocampus | Wistar rat | Up |
| Study M947 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M947 | Type2 | CUMS + middle dose of Chaigui granules group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M947 | Type2 | CUMS + high dose of Chaigui granules group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M981 | Type1 | Abeta oligomer group vs. control group | Serum | ICR mouse | Up |
| Study M981 | Type2 | Abeta oligomer + involuntary and voluntary running group vs. Abeta oligomer group | Serum | ICR mouse | Down |
| Study M981 | Type2 | Abeta oligomer + involuntary and voluntary running + acousto-optic stimulation group vs. Abeta oligomer group | Serum | ICR mouse | Down |